02:27 PM EDT, 04/23/2024 (MT Newswires) -- Lixte Biotechnology ( LIXT ) on Tuesday filed a registration statement covering the potential sale of up to $50 million in securities.

The filing covers common shares, preferred shares, debt securities, warrants, rights, and units.

Unless otherwise stated in a prospectus supplement, net proceeds from the sale will be used for working capital, capital expenditures, research and development costs, and other general corporate purposes.

Price: 3.53, Change: +0.22, Percent Change: +6.65